$BNET
BION ENVIRONMENTAL TECHNOLOGIES INC

2020 Q4 Form 10-Q Financial Statement

#000107997321000065 Filed on February 08, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2019 Q4 2019
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $291.7K $387.5K $1.725M
YoY Change -24.73% 33.82% -26.15%
% of Gross Profit
Research & Development $155.4K $114.5K $237.8K
YoY Change 35.76% 0.23% -79.94%
% of Gross Profit
Depreciation & Amortization $207.00 $347.00 $694.00
YoY Change -40.35% 33.98% -60.21%
% of Gross Profit
Operating Expenses $447.3K $502.3K $946.2K
YoY Change -10.96% 24.32% -73.14%
Operating Profit -$447.3K -$502.3K -$946.2K
YoY Change -10.96% 24.32% -73.14%
Interest Expense $303.2K $142.7K $260.3K
YoY Change 112.4% 46.69% -27.78%
% of Operating Profit
Other Income/Expense, Net -$303.2K -$142.7K -$260.3K
YoY Change 112.4% 46.69% -151.6%
Pretax Income -$750.5K -$645.1K -$2.659M
YoY Change 16.34% 28.67% -11.89%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$750.4K -$645.1K -$2.659M
YoY Change 16.34% 28.66% -11.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$24.05K -$22.37K -$100.1K
COMMON SHARES
Basic Shares Outstanding 30.15M
Diluted Shares Outstanding 31.19M 28.80M 26.52M

Balance Sheet

Concept 2020 Q4 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $361.2K $469.2K $41.34K
YoY Change -23.02% 1008.6% 87.82%
Cash & Equivalents $361.2K $469.2K
Short-Term Investments
Other Short-Term Assets $5.350K $1.000K $9.010K
YoY Change 435.0% -61.69% 6.38%
Inventory
Prepaid Expenses $4.350K
Receivables
Other Receivables $1.000K
Total Short-Term Assets $366.5K $470.2K $50.34K
YoY Change -22.04% 946.46% 65.1%
LONG-TERM ASSETS
Property, Plant & Equipment $954.00 $1.922K $2.620K
YoY Change -50.36% 12.33% 80.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $954.00 $1.922K $2.620K
YoY Change -50.36% 12.33% 80.69%
TOTAL ASSETS
Total Short-Term Assets $366.5K $470.2K $50.34K
Total Long-Term Assets $954.00 $1.922K $2.620K
Total Assets $367.5K $472.1K $52.96K
YoY Change -22.16% 912.19% 65.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $701.3K $715.6K
YoY Change -14.44% 8.95% -0.57%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.755M $9.445M $9.303M
YoY Change 3.29% 3.1% 3.04%
Total Short-Term Liabilities $11.39M $10.72M $10.93M
YoY Change 6.31% 1.73% 7.1%
LONG-TERM LIABILITIES
Long-Term Debt $4.710M $4.523M $3.801M
YoY Change 4.14% 26.06% 7.83%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.710M $4.523M $3.801M
YoY Change 4.14% 26.06% 7.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.39M $10.72M $10.93M
Total Long-Term Liabilities $4.710M $4.523M $3.801M
Total Liabilities $16.10M $15.24M $14.78M
YoY Change 5.67% 7.91% 7.23%
SHAREHOLDERS EQUITY
Retained Earnings -$130.1M -$125.6M
YoY Change 3.65% 1.97%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$15.78M -$14.82M -$14.72M
YoY Change
Total Liabilities & Shareholders Equity $367.5K $472.1K $52.96K
YoY Change -22.16% 912.19% 65.81%

Cashflow Statement

Concept 2020 Q4 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$750.4K -$645.1K -$2.659M
YoY Change 16.34% 28.66% -11.9%
Depreciation, Depletion And Amortization $207.00 $347.00 $694.00
YoY Change -40.35% 33.98% -60.21%
Cash From Operating Activities -$281.4K -$325.8K -$811.1K
YoY Change -13.62% 69.99% 73.55%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.482K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$2.482K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 306.5K 720.3K 832.9K
YoY Change -57.45% 1260.93% 100.0%
NET CHANGE
Cash From Operating Activities -281.4K -325.8K -811.1K
Cash From Investing Activities 0.000 -2.482K
Cash From Financing Activities 306.5K 720.3K 832.9K
Net Change In Cash 25.08K 394.5K 19.32K
YoY Change -93.64% -384.39% -137.95%
FREE CASH FLOW
Cash From Operating Activities -$281.4K -$325.8K -$811.1K
Capital Expenditures $0.00 $2.482K
Free Cash Flow -$325.8K -$813.6K
YoY Change 69.99% 74.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
bnet Weighted Average Exercise Price For Outstanding Warrants
WeightedAverageExercisePriceForOutstandingWarrants
0.74
CY2020Q4 bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
316298
CY2019Q4 bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
1090714
bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
285943
bnet Adjustment To Additional Paid In Capital Modification Of Warrants
AdjustmentToAdditionalPaidInCapitalModificationOfWarrants
35339
bnet Adjustment To Additional Paid In Capital Modification Of Warrants
AdjustmentToAdditionalPaidInCapitalModificationOfWarrants
188890
bnet Adjustment To Additional Paid In Capital Modification Ofoptions
AdjustmentToAdditionalPaidInCapitalModificationOfoptions
8775
bnet Common Stock Voting Rights Votes Per Share
CommonStockVotingRightsVotesPerShare
1
CY2020Q4 bnet Computers And Office Equipment Gross
ComputersAndOfficeEquipmentGross
171485
CY2020Q2 bnet Computers And Office Equipment Gross
ComputersAndOfficeEquipmentGross
171485
bnet Conversion Of Debt And Liabilities
ConversionOfDebtAndLiabilities
70794
bnet Conversion Of Debt And Liabilities
ConversionOfDebtAndLiabilities
71658
bnet Conversion Of Deferred Compensation Into Note Payable Affiliate
ConversionOfDeferredCompensationIntoNotePayableAffiliate
bnet Conversion Of Deferred Compensation Into Note Payable Affiliate
ConversionOfDeferredCompensationIntoNotePayableAffiliate
636081
bnet Deferred Compensation Consecutive Trading Days
DeferredCompensationConsecutiveTradingDays
P10D
bnet Deferred Compensation Conversion Days
DeferredCompensationConversionDays
P5D
CY2018 bnet Deferred Compensation Liability Amount Cancelled
DeferredCompensationLiabilityAmountCancelled
2404000
CY2013Q2 bnet Extension Of Exercise Period Annual Payment Per Option Or Warrant
ExtensionOfExercisePeriodAnnualPaymentPerOptionOrWarrant
0.05
CY2020Q4 bnet Interest Rate On Deferred Compensation
InterestRateOnDeferredCompensation
0.04
CY2020Q4 bnet Loans Payable Current Including Accrued Interest And Late Charges
LoansPayableCurrentIncludingAccruedInterestAndLateCharges
9727189
CY2020Q2 bnet Loans Payable Current Including Accrued Interest And Late Charges
LoansPayableCurrentIncludingAccruedInterestAndLateCharges
9585883
bnet Loans Payable To Affiliates
LoansPayableToAffiliates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">5.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LOANS PAYABLE:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Pennvest</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic; font: inherit;">PA1,</div> the Company's wholly-owned subsidiary, owes <div style="display: inline; font-style: italic; font: inherit;">$9,727,189</div> as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>under the terms of the Pennvest Loan related to the construction of the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> System including accrued interest and late charges totaling <div style="display: inline; font-style: italic; font: inherit;">$1,973,189</div> as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020. </div>The terms of the Pennvest Loan provided for funding of up to <div style="display: inline; font-style: italic; font: inherit;">$7,754,000</div> which was to be repaid by interest-only payments for <div style="display: inline; font-style: italic; font: inherit;">three</div> years, followed by an additional <div style="display: inline; font-style: italic; font: inherit;">ten</div>-year amortization of principal. The Pennvest Loan accrues interest at <div style="display: inline; font-style: italic; font: inherit;">2.547%</div> per annum for years <div style="display: inline; font-style: italic; font: inherit;">1</div> through <div style="display: inline; font-style: italic; font: inherit;">5</div> and <div style="display: inline; font-style: italic; font: inherit;">3.184%</div> per annum for years <div style="display: inline; font-style: italic; font: inherit;">6</div> through maturity. The Pennvest Loan required minimum annual principal payments of approximately <div style="display: inline; font-style: italic; font: inherit;">$5,067,000</div> in fiscal years <div style="display: inline; font-style: italic; font: inherit;">2013</div> through <div style="display: inline; font-style: italic; font: inherit;">2020,</div> and <div style="display: inline; font-style: italic; font: inherit;">$819,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2021,</div> <div style="display: inline; font-style: italic; font: inherit;">$846,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2022,</div> <div style="display: inline; font-style: italic; font: inherit;">$873,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2023</div> and <div style="display: inline; font-style: italic; font: inherit;">$149,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2024.</div> The Pennvest Loan is collateralized by the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> System and by a pledge of all revenues generated from Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> including, but <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest is entitled to participate in the profits from Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$61,722</div></div> for both the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively. The Company has also incurred interest expense related to the Pennvest Loan of <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$123,444</div></div> for both the <div style="display: inline; font-style: italic; font: inherit;">six</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market to date, <div style="display: inline; font-style: italic; font: inherit;">PA1</div> commenced negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan. In the context of such negotiations, <div style="display: inline; font-style: italic; font: inherit;">PA1</div> has elected <div style="display: inline; font-style: italic; font: inherit;">not</div> to make interest payments to Pennvest on the Pennvest Loan since <div style="display: inline; font-style: italic; font: inherit;"> January 2013. </div>Additionally, the Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> made any principal payments, which were to begin in fiscal <div style="display: inline; font-style: italic; font: inherit;">2013,</div> and, therefore, the Company has classified the Pennvest Loan as a current liability as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <div style="display: inline; font-style: italic; font: inherit;"> September 25, 2014, </div>Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and demanded that <div style="display: inline; font-style: italic; font: inherit;">PA1</div> pay <div style="display: inline; font-style: italic; font: inherit;">$8,137,117</div> (principal, interest plus late charges) on or before <div style="display: inline; font-style: italic; font: inherit;"> October 24, 2014. </div><div style="display: inline; font-style: italic; font: inherit;">PA1</div> did <div style="display: inline; font-style: italic; font: inherit;">not</div> make the payment and does <div style="display: inline; font-style: italic; font: inherit;">not</div> have the resources to make the payment demanded by Pennvest. <div style="display: inline; font-style: italic; font: inherit;">PA1</div> has engaged in on/off discussions and negotiations with Pennvest concerning this matter but <div style="display: inline; font-style: italic; font: inherit;">no</div> such discussions/negotiations are currently active. As of the date of this report, <div style="display: inline; font-style: italic; font: inherit;">no</div> proposals (formal or informal) are under consideration and only sporadic communication has taken place regarding the matters involved in over <div style="display: inline; font-style: italic; font: inherit;">5</div> years. It is <div style="display: inline; font-style: italic; font: inherit;">not</div> possible at this date to predict the outcome of this matter given the extended period which has passed without resolution and the fact that the technology employed in the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> system is now outdated. However, the Company believes that a loan modification agreement (coupled with an agreement regarding an update and restart of the full operation of Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> <div style="display: inline; font-style: italic; font: inherit;"> may </div>in the future be possible in conjunction with the Kreider <div style="display: inline; font-style: italic; font: inherit;">2</div> project, subject to the results of the negotiations with Pennvest and pending development of a more robust market for nutrient reductions in Pennsylvania. The Covid-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic has further increased uncertainties. <div style="display: inline; font-style: italic; font: inherit;">PA1</div> and Bion will continue to evaluate various options with regard to Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> over the next <div style="display: inline; font-style: italic; font: inherit;">six</div> to <div style="display: inline; font-style: italic; font: inherit;">twelve</div> months.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In connection with the Pennvest Loan financing documents, the Company provided a &#x2018;technology guaranty' regarding nutrient reduction performance of Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> which was structured to expire when Kreider <div style="display: inline; font-style: italic; font: inherit;">1's</div> nutrient reduction performance had been demonstrated. During <div style="display: inline; font-style: italic; font: inherit;"> August 2012 </div>the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> System had surpassed the requisite performance criteria and that the Company's &#x2018;technology guaranty' was met. As a result, the Pennvest Loan is solely an obligation of <div style="display: inline; font-style: italic; font: inherit;">PA1.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Paycheck Protection Program</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">During the year ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020, </div>the Company received proceeds from a loan in the amount of <div style="display: inline; font-style: italic; font: inherit;">$34,800</div> from Covenant Bank as the lender, pursuant to the Small Business Administration (&#x201c;SBA&#x201d;) Paycheck Protection Program (&#x201c;PPP&#x201d;) under the Coronavirus Aid, Relief, and Economic Security (&#x201c;CARES&#x201d;) Act. The loan is uncollateralized, has a fixed interest rate of <div style="display: inline; font-style: italic; font: inherit;">one</div> percent, a term of <div style="display: inline; font-style: italic; font: inherit;">two</div> years and the <div style="display: inline; font-style: italic; font: inherit;">first</div> payment is deferred for <div style="display: inline; font-style: italic; font: inherit;">six</div> months. Under the CARES Act, borrowers are eligible for forgiveness of principal and interest on PPP loans to the extent that the proceeds were used to cover eligible payroll costs, rent and utility costs over either an <div style="display: inline; font-style: italic; font: inherit;">8</div>- or <div style="display: inline; font-style: italic; font: inherit;">24</div>-week period after the loan was made. As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the total PPP loan and accrued interest was <div style="display: inline; font-style: italic; font: inherit;">$35,026.</div> Management believes that the Company has met the conditions for full forgiveness of the PPP loan and will be applying for forgiveness once Covenant Bank and the SBA are ready to accept applications.</div></div>
bnet Proceeds From The Sale Of Units
ProceedsFromTheSaleOfUnits
360000
bnet Proceeds From The Sale Of Units
ProceedsFromTheSaleOfUnits
977000
bnet Sale Of Units Value
SaleOfUnitsValue
977000
bnet Sale Of Units Value
SaleOfUnitsValue
360000
CY2020Q4 bnet Shares Held By Subsidiaries
SharesHeldBySubsidiaries
704309
CY2019Q4 bnet Shares Held By Subsidiaries
SharesHeldBySubsidiaries
704309
bnet Stock Issued During Period Value Commissions On Sale Of Units
StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits
87200
bnet Stock Issued During Period Value Commissions On Sale Of Units
StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits
31000
bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
771030
bnet Weighted Average Remaining Contractual Life For Outstanding Warrants
WeightedAverageRemainingContractualLifeForOutstandingWarrants
P3Y73D
CY2020Q4 bnet Working Capital
WorkingCapital
-11028000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
604255
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
628926
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2794671
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2794257
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114866642
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114266683
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
99500
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2500
CY2020Q4 us-gaap Assets
Assets
367488
CY2020Q2 us-gaap Assets
Assets
571161
CY2020Q4 us-gaap Assets Current
AssetsCurrent
366534
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
560828
CY2020Q2 us-gaap Assets Current
AssetsCurrent
569793
CY2020Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
401470
CY2020Q2 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
401470
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41335
CY2020Q4 us-gaap Cash
Cash
361184
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
469164
CY2020Q2 us-gaap Cash
Cash
560828
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
361184
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-199644
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
427829
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21300000
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
504650
CY2020Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
504650
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32270594
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31409005
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31575656
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28417602
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28068688
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31566285
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30704696
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30871347
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27713293
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27364379
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Concentrations of credit risk:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times <div style="display: inline; font-style: italic; font: inherit;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses on such accounts.</div></div></div>
CY2009Q1 us-gaap Construction Loan
ConstructionLoan
7750000
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4703000
CY2020Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4595841
CY2020Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
998474
CY2019Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
537119
CY2020Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
778217
CY2020Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1000
CY2020Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1000
CY2020Q4 us-gaap Depreciation
Depreciation
207
CY2019Q4 us-gaap Depreciation
Depreciation
347
us-gaap Depreciation
Depreciation
414
us-gaap Depreciation
Depreciation
694
CY2020 us-gaap Depreciation
Depreciation
414
CY2019 us-gaap Depreciation
Depreciation
694
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
291682
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
387526
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
594559
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
707754
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8162
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
38575
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
245742
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
288204
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3615
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-8005
CY2020Q4 us-gaap Interest Expense
InterestExpense
303171
CY2019Q4 us-gaap Interest Expense
InterestExpense
142738
CY2020 us-gaap Interest Expense
InterestExpense
407511
CY2019 us-gaap Interest Expense
InterestExpense
260340
us-gaap Interest Paid Net
InterestPaidNet
28
us-gaap Interest Paid Net
InterestPaidNet
CY2020Q4 us-gaap Liabilities
Liabilities
16104344
CY2020Q2 us-gaap Liabilities
Liabilities
15659119
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
367488
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
571161
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11394051
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11043359
CY2020Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2222670
CY2020Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2222670
CY2020Q4 us-gaap Minority Interest
MinorityInterest
40863
CY2020Q2 us-gaap Minority Interest
MinorityInterest
41902
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
329000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
904800
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-528644
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-476971
CY2020Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-524
CY2019Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-768
CY2020 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1039
CY2019 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1273
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-749921
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-644297
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1247818
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1205294
CY2020Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-303171
CY2019Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-142738
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-407511
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-260340
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
447274
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
502327
CY2020 us-gaap Operating Expenses
OperatingExpenses
841346
CY2019 us-gaap Operating Expenses
OperatingExpenses
946227
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-447274
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-502327
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-841346
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-946227
us-gaap Other Noncash Expense
OtherNoncashExpense
425499
us-gaap Other Noncash Expense
OtherNoncashExpense
278268
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
31000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
87200
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4350
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7965
CY2020 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1584000
CY2019 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
897000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
360000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
35000
CY2020 us-gaap Profit Loss
ProfitLoss
-4553000
CY2019 us-gaap Profit Loss
ProfitLoss
-2659000
us-gaap Profit Loss
ProfitLoss
-1248857
us-gaap Profit Loss
ProfitLoss
-1206567
CY2020Q4 us-gaap Profit Loss
ProfitLoss
-750445
CY2019Q4 us-gaap Profit Loss
ProfitLoss
-645065
CY2020 us-gaap Profit Loss
ProfitLoss
-1248857
CY2019 us-gaap Profit Loss
ProfitLoss
-1206567
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2795625
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2795625
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
954
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1368
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
20000
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
155385
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
114454
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
246373
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
237779
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-130139711
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128891893
CY2020Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2019Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9511600
us-gaap Share Based Compensation
ShareBasedCompensation
36781
us-gaap Share Based Compensation
ShareBasedCompensation
115850
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9511600
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9511600
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.74
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.74
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28804007
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30990639
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y182D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
99500
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2020Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
36400
CY2020Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
35400
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
71658
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
70794
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
16350
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-15777719
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-15129860
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14674598
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14768518
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15087958
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15736856
CY2020Q4 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
27733
CY2020Q2 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
14933
CY2020Q4 us-gaap Unsecured Long Term Debt
UnsecuredLongTermDebt
7293
CY2020Q2 us-gaap Unsecured Long Term Debt
UnsecuredLongTermDebt
19919
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Use of estimates:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In preparing the Company's consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div>
CY2020Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31187645
CY2019Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28804007
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30990639
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28135409
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31187645
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28135409

Files In Submission

Name View Source Status
0001079973-21-000065-index-headers.html Edgar Link pending
0001079973-21-000065-index.html Edgar Link pending
0001079973-21-000065.txt Edgar Link pending
0001079973-21-000065-xbrl.zip Edgar Link pending
bion_10q-123120.htm Edgar Link pending
bnet-20201231.xml Edgar Link completed
bnet-20201231.xsd Edgar Link pending
bnet-20201231_cal.xml Edgar Link unprocessable
bnet-20201231_def.xml Edgar Link unprocessable
bnet-20201231_lab.xml Edgar Link unprocessable
bnet-20201231_pre.xml Edgar Link unprocessable
ex31x1.htm Edgar Link pending
ex31x2.htm Edgar Link pending
ex32x1.htm Edgar Link pending
ex32x2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending